08:00 , Dec 5, 2011 |  BioCentury  |  Finance

The full Montigen

The full Montigen After five years of asset accumulation, Astex Pharmaceuticals Inc. (NASDAQ:ASTX) has decided it has more than a full plate, including a pair of cancer drug discovery platforms, a drug on the market...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Company News

Ascalon, CerRx deal

CerRx granted Ascalon an exclusive option to license worldwide rights to develop and commercialize fenretinide. The IV vitamin A analog has completed Phase I testing to treat T cell lymphomas and solid tumors including esophageal...